Omega Diagnostics Group PLC (ODX.L) Mologic CE Mark Rapid Antigen Test

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, welcomes the news that Mologic Ltd (“Mologic”) has received CE Mark for it’s professional-use COVID-19 Rapid Antigen Test.

In June this year, the Company signed a material transfer agreement (“MTA”) with Mologic providing access to raw materials and know-how to manufacture their lateral flow antigen test. The test will provide health professionals an accurate detection of the nucleoprotein of the SARS-CoV-2 virus in respiratory swabs.

As announced at the Interim results in November 2020, Omega has now established its technology transfer team and look forward to updating shareholders in the New Year on how the technology transfer and CE Mark is going, so the Company can sell the Rapid Test under Omega’s VISITECT ® brand.

Colin King, CEO of Omega Diagnostics, said: “We welcome the news that Mologic has received CE Mark for its Rapid Antigen Test, and are excited about completing the technology transfer and CE Marking in the New Year.”

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.